NEW YORK--(BUSINESS WIRE)--Flatiron Health today announced a new agreement to bring Flatiron Assist™ advanced cancer care insights to oncology care clinicians at Penn Medicine’s Abramson Cancer Center (ACC).

纽约-Flatiron Health今天宣布了一项新协议，要求提供Flatiron协助™ Penn Medicine的Abramson癌症中心（ACC）的肿瘤护理临床医生的高级癌症护理见解。

The collaboration between Flatiron Health and Penn Medicine will focus on further enabling clinicians at ACC to determine and promote site-preferred pathways and open clinical trials at the point of care alongside the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®). Access to evidence-based treatment recommendations will promote high levels of guideline-concordant care, while improving health equity and patient experiences and reducing unnecessary spending.

Flatiron Health与Penn Medicine之间的合作将集中于进一步使ACC的临床医生能够确定和促进现场首选途径，并与NCCN肿瘤临床实践指南（NCCN Guidelines®）一起在护理点开展临床试验。获得循证治疗建议将促进高水平的指南一致性护理，同时改善健康公平和患者体验，减少不必要的支出。

The two organizations will also work together to optimize the usability and functionality of Flatiron Assist™..

这两个组织还将共同努力，优化Flatiron Assist的可用性和功能™..

Flatiron Assist™ is an oncology-specific clinical decision support platform that prioritizes the latest evidence-based medicine, site-preferred pathways and clinical research at the point of care. The EHR-integrated platform incorporates NCCN Guidelines for the 26 most common cancers as well as site-preferred treatment pathways and relevant clinical trial opportunities for patients at the point of care..

Flatiron协助™ 是一个针对肿瘤学的临床决策支持平台，优先考虑最新的循证医学，现场首选途径和临床研究。EHR综合平台纳入了针对26种最常见癌症的NCCN指南，以及针对护理点患者的现场首选治疗途径和相关临床试验机会。。

Flatiron Assist™’s high provider adoption has driven positive outcomes for cancer centers, yielding results such as an 88% concordance with NCCN guidelines¹ and a 44% reduction in unique regimens ordered across cancer centers.²

Flatiron协助™’高供应商的采用为癌症中心带来了积极成果，其结果如与NCCN指南的一致性为88%，在癌症中心订购的独特方案减少了44%。²

“At Flatiron, we are committed to elevating clinical care and unlocking the power of patient data, so every person’s experience can inform and improve outcomes for future patients. Partnering with Penn Medicine’s Abramson Cancer Center, a market-leading cancer care provider and a pioneer of digital innovation in healthcare, enables us to use data for good and reimagine the infrastructure of cancer care,” said Julia Morton SVP and GM of Flatiron HC.

“在Flatiron，我们致力于提升临床护理并释放患者数据的力量，因此每个人的经验都可以为未来患者提供信息并改善结果。与Penn Medicine的Abramson癌症中心合作，该中心是市场领先的癌症护理提供者，也是医疗保健数字创新的先驱，使我们能够将数据用于良好和重新设计基础设施癌症护理，”Flatiron HC的Julia Morton SVP和GM说。

“We are looking forward to working together to accelerate the delivery of more standardized, efficient, and effective cancer care across the entire health system.”.

“我们期待着共同努力，加速在整个卫生系统中提供更加标准化，高效和有效的癌症护理。”。

The goals of this collaboration include launching Flatiron Assist™ with NCCN preferred guidelines across all diseases while working to develop ACC-preferred pathways across specialized diseases. Flatiron Assist drives over 84% selection of site-preferred regimens across users at cancer centers.³

这项合作的目标包括推出Flatiron Assist™ NCCN在所有疾病中首选指南，同时努力开发跨专门疾病的ACC首选途径。Flatiron协助推动癌症中心用户选择84%以上的首选治疗方案。³

The project will also aim to leverage Flatiron Assist™ technology to increase awareness of clinical trial opportunities and drive user adoption and satisfaction. On average, Flatiron Assist™ users typically see 80% clinician adoption.⁴ The two organizations will track usage patterns and tie the results to financial impacts for the health system..

该项目还将旨在利用Flatiron协助™ 技术，以提高对临床试验机会的认识，并推动用户的采用和满意度。平均而言，Flatiron协助™ 用户通常会看到80%的临床医生采用。⁴ 这两个组织将跟踪使用模式，并将结果与​​卫生系统的财务影响联系起来。。

“We are excited to support our oncology clinicians in providing evidence-based treatment while improving clinical and administrative efficiencies,” said Lawrence N. Shulman, MD, a professor of Medicine in the Perelman School of Medicine at the University of Pennsylvania and the associate director of special projects at ACC.

宾夕法尼亚大学佩雷尔曼医学院医学教授，副主任Lawrence N.Shulman博士说：“我们很高兴支持我们的肿瘤临床医生提供循证治疗，同时提高临床和行政效率。”ACC特别项目主任。

“As cancer care options increase in complexity, this tool will help provide high-quality, guideline-concordant care, maximizing benefits for our patients.”.

“随着癌症护理方案的复杂性增加，该工具将有助于提供高质量，指南一致的护理，最大限度地为患者带来益处。”。

About Flatiron Health

关于Flatiron健康

Flatiron Health is a healthtech company expanding the possibilities for point of care solutions in oncology and using data for good to power smarter care for every person with cancer. Through machine learning and AI, real-world evidence, and breakthroughs in clinical trials, we continue to transform patients’ real-life experiences into knowledge and create a more modern, connected oncology ecosystem.

Flatiron Health是一家healthtech公司，致力于扩大肿瘤学护理点解决方案的可能性，并使用数据为每个癌症患者提供更好的智能护理。通过机器学习和人工智能，现实世界的证据以及临床试验的突破，我们继续将患者的现实生活经验转化为知识，并创建一个更加现代化，相互联系的肿瘤生态系统。

Flatiron Health is an independent affiliate of the Roche Group. Flatiron.com @FlatironHealth.

Flatiron Health是罗氏集团的独立分支机构。Flatiron.com@FlatironHealth。

References

工具书类

Jonas M. Congelli, Rebecca Maniago, Stephanie Jou, Janet Donegan and Ivy Altomare. Official Journal of the National Comprehensive Cancer Network. Volume 20: Issue 3.5, March 31, 2022. https://jnccn.org/view/journals/jnccn/20/3.5/article-pBPI22-015.xml#:~:text=https%3A//doi.org/10.6004/jnccn.2021.7262.

Jonas M.Congelli，Rebecca Maniago，Stephanie Jou，Janet Donegan和Ivy Altomare。国家综合癌症网络官方杂志。第20卷：第3.5期，2022年3月31日。https://jnccn.org/view/journals/jnccn/20/3.5/article-pBPI22-015.xml#:〜：text=https%3A//doi.org/10.6004/jnccn.2021.7262。

Jonas M. Congelli, Heather Lewin, Gregory Calip, Marcello Ricottone, Shawn Huda, Taylor Dias-Foundas and Rebecca Maniago. Official Journal of the National Comprehensive Cancer Network. Volume 21: Issue 3.5, March 31, 2023. https://jnccn.org/view/journals/jnccn/21/3.5/article-pQIM23-132.xml

Jonas M.Congelli，Heather Lewin，Gregory Calip，Marcello Ricottone，Shawn Huda，Taylor Dias Foundas和Rebecca Maniago。国家综合癌症网络官方杂志。第21卷：第3.5期，2023年3月31日。https://jnccn.org/view/journals/jnccn/21/3.5/article-pQIM23-132.xml

Rebecca Maniago, Marcello Ricottone, Gregory Calip, Taylor Dias-Foundas, James Hamrick. Journal of Clinical Pathways. 2023;9(3):22-24. doi:10.25270/jcp.2023.05.02 https://www.hmpgloballearningnetwork.com/site/jcp/research-reports/can-we-fill-gaps-authoring-custom-oncology-pathways-vs-surfacing-nccn

Rebecca Maniago，Marcello Ricottone，Gregory Calip，Taylor Dias Foundas，James Hamrick。临床路径杂志。2023;9（3）：22-24。doi:10.25270/jcp.2023.05.02https://www.hmpgloballearningnetwork.com/site/jcp/research-reports/can-we-fill-gaps-authoring-custom-oncology-pathways-vs-surfacing-nccn

Rebecca Maniago, Sylvia S. Richey, Sarah DeVincenzo, Stephanie Jou, Robin Linzmayer, Janet Donegan, Gregory Sampang Calip, Ivy Altomare. Journal of Clinical Oncology. Volume 39: Issue 28_suppl, 274-274 https://ascopubs.org/doi/abs/10.1200/JCO.2020.39.28_suppl.274?af=R

Rebecca Maniago，Sylvia S.Richey，Sarah DeVincenzo，Stephanie Jou，Robin Linzmayer，Janet Donegan，Gregory Sampang Calip，Ivy Altomare。临床肿瘤学杂志。第39卷：问题28_suppl，274-274https://ascopubs.org/doi/abs/10.1200/JCO.2020.39.28_suppl.274?af=R